CSIMarket
 
Integra Lifesciences Holdings Corp  (IART)
Other Ticker:  
 
 
Price: $34.2400 $-0.46 -1.326%
Day's High: $34.83 Week Perf: -4.57 %
Day's Low: $ 34.17 30 Day Perf: -23.49 %
Volume (M): 762 52 Wk High: $ 59.33
Volume (M$): $ 26,101 52 Wk Avg: $43.15
Open: $34.69 52 Wk Low: $33.44



 Market Capitalization (Millions $) 2,761
 Shares Outstanding (Millions) 81
 Employees 4,500
 Revenues (TTM) (Millions $) 1,542
 Net Income (TTM) (Millions $) 68
 Cash Flow (TTM) (Millions $) -180
 Capital Exp. (TTM) (Millions $) 67

Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp is a leading global medical technology company that produces a wide range of innovative and advanced surgical products and devices. The company provides products and solutions for orthopedic and tissue regeneration surgeries, neurosurgery, reconstructive and general surgery, and wound care. Founded in 1989, Integra Lifesciences is headquartered in Plainsboro, New Jersey, and operates in more than 100 countries worldwide.

Products and Services:

The company produces a broad range of surgical products and devices, including:

1. Orthopedic Products: These products are used to treat and repair musculoskeletal injuries, including fractures, soft tissue injuries, and degenerative conditions. Integra Lifesciences offers a range of bone graft substitutes, fixation systems, and instruments for orthopedic surgeons.

2. Tissue Regeneration Products: These products are used to repair and regenerate tissues including skin, bone, and nerves. Integra Lifesciences offers advanced solutions for tissue engineering, wound care, and regenerative medicine.

3. Neurosurgical Products: These products are used in neurosurgery to treat conditions such as brain tumors, skull base surgery, and spinal surgery. Integra Lifesciences provides a diverse range of neurosurgical devices, including cranial fixation systems, neurosurgical instruments, and neuro-monitoring products.

4. Reconstructive and General Surgery Products: These products are used in procedures to restore function and aesthetic appearance after traumatic injuries, cancers or other diseases. Integra Lifesciences provides devices and products for reconstructive surgery of the breast, face, and abdomen.

Operating Segments:

Integra Lifesciences operates through three main segments:

1. Codman Specialty Surgical: This segment is focused on neurosurgery and provides devices and instruments for cranial, spinal, and peripheral nerve surgical procedures.

2. Orthopedics and Tissue Technologies: This segment provides products and devices for orthopedics, wound care, and tissue regeneration.

3. Private Label: This segment provides a range of surgical instruments, such as ear, nose, and throat (ENT) instruments, and surgical implants and equipment to medical device companies.

Acquisitions:

Over the years, Integra Lifesciences has made several strategic acquisitions to enhance its product portfolio and expand its market reach. In 2017, the company acquired Codman Neurosurgery from Johnson & Johnson for $1.05 billion, which includes a portfolio of surgical instruments and devices for neurosurgery.

In 2014, Integra Lifesciences acquired the Derma Sciences wound care business to expand its portfolio of wound care solutions. In 2012, the company bought Ascension Orthopedics, a manufacturer of implants for upper extremity surgical procedures.

Conclusion:

Integra Lifesciences is a leading global medical technology company that offers a wide range of innovative and advanced surgical products and devices. The company's products help surgeons and healthcare professionals to improve patient outcomes and quality of life. With a strong focus on research and development, manufacturing expertise, and global distribution network, Integra Lifesciences is well-positioned to continue providing innovative solutions for the medical industry.


   Company Address: 1100 Campus Road Princeton 8540 NJ
   Company Phone Number: 275-0500   Stock Exchange / Ticker: NASDAQ IART
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Integra LifeSciences Unveils MicroMatrix Flex, Transforming Surgical Approach to Complex Cases

Published Mon, Mar 11 2024 12:30 PM UTC

Integra LifeSciences Revolutionizes Surgical Procedures with the Launch of MicroMatrix FlexIntegra LifeSciences, a leading global medical technology company, has announced the introduction of MicroMatrix Flex, a cutting-edge system designed to provide convenient access to hard-to-reach areas during complex surgical cases. This novel system combines the flexibility of its tip...

Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp Reports Steep Decline in Earnings Per Share for Fourth Quarter of 2023

Integra Lifesciences Holdings Corp, a leading global medical technology company, recently announced its financial results for the fourth quarter and full year of 2023. The company revealed a decline in earnings per share by -60.46% to $0.25 and a decrease in revenue by -0.247% to $397.04 million in the financial fourth quarter of 2023 compared to the previous year. Despite this decline, the Medical Equipment & Supplies sector recorded a revenue rise in the fourth quarter of 2023.
Looking further into the financial fourth quarter of 2023, Integra Lifesciences Holdings Corp's profitability metrics showed a decrease. The operating margin mitigated to 9.08%, and the net margin shrank to 5%. Net income fell by -62.54% to $19.834 million in the fourth quarter of 2023 compared to the corresponding period a year before. Additionally, operating earnings fell by -46.86% to $36.047 million, squeezing Integra Lifesciences Holdings Corp's operating margin to 9.08% from 17.04% in the fourth quarter of 2022.

Management Changes

Integra Lifesciences Announces Leadership Transition Plan amid Positive Financial Performance

Published Wed, Feb 28 2024 11:00 AM UTC



Integra Lifesciences Holdings Corp, a leading medical technology company, has recently made significant leadership changes and achieved commendable financial results. These developments showcase Integra's commitment to innovation and growth in the healthcare sector. As the company prepares for a transition in its leadership team, investors and stakeholders eagerly ...

Integra Lifesciences Holdings Corp

Integra Lifesciences' Impressive Resilience: Barely Any Drop in Revenue for Q3 2023!

Integra Lifesciences Holdings Corp (IART) recently disclosed a decline in earnings per share (EPS) by 60% to $0.24 and a slight decrease in revenue by 0.719% to $382.42 million in the most recent fiscal period compared to the previous year. However, it is worth noting that EPS showed a significant improvement from the previous quarter, increasing from $0.05 per share, and the revenue also saw a slight increase of 0.303% from $381.27 million.
In terms of net earnings, Integra Lifesciences Holdings Corp experienced a sharp decline of 60.94% to $19.497 million in the most recent fiscal period, compared to $49.915 million in the corresponding period a year before. This decrease in net earnings raises concerns about the company's overall financial performance.

Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp Reports a Moderate Decline in Revenue for the Fiscal Period Ending June 30, 2023, amidst a Sharp Reduction in Income and EPS



Integra Lifesciences Holdings Corp, a renowned company operating in the medical technology space, recently released its financial results for the period of April to June 2023. The impact of these results on the company's income, revenue, profitability, and other key metrics offers valuable insights into its future prospects. This article explores these facts and ponders over their potential impact on the company's trajectory moving forward.
1. Plummeting Income and Earnings:
During the April to June 2023 period, Integra Lifesciences witnessed a significant decline in its income and earnings. Income fell sharply by -90.74% to $0.05 per share, compared to $0.54 per share the previous year. Additionally, earnings dropped by -90.66% to $4.184 million from $44.788 million in the same period last year. This substantial decrease raises concerns about the company's financial performance and prompts the need to identify the underlying causes.






 

Integra Lifesciences Holdings's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Integra Lifesciences Holdings does not provide revenue guidance.

Earnings Outlook
Integra Lifesciences Holdings Corp does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com